Clinical trial NCT02208934: Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers
Official title: Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Huntington's Disease
Keywords: PDE10 inhibitor
Huntington's disease
phosphodiesterase 10 inhibitor
psychiatric disorders
Lead sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor class: OTHER
Collaborators: name: Palo Biofarma, S.L
First posted: 2014-08-05
Enrollment: 32
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers


Eligibility criteria: Inclusion Criteria:

1. Healthy male subjects, 18-45 years (inclusive) of age at the time of enrollment.
2. Males should agree to abstain from sexual intercourse with a female partner or agree to use a condom with spermicide, in addition to having their female partner use some contraceptive measures until 28 days post-administration.
3. Clinically acceptable blood pressure and pulse rate in supine and standing position. Blood pressure and pulse will be measured after a minimum of 3 minutes of resting.
4. Body weight within normal range (Quetelet's index between 19 and 26) expressed as weight (kg) / height (m2).
5. Able to understand the nature of the study and comply with all their requirements.
6. Free acceptance to participate in the study by obtains signed informed consent form approved by the Ethics Committee of the Hospital (CEIC).

Exclusion Criteria:

1. History of serious adverse reactions or hypersensitivity to any drug.
2. Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
3. Background or clinical evidence of chronic diseases.
4. Acute illness two weeks before drug administration.
5. Having undergone major surgery during the previous 6 months.
6. Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the administration of the study medication.
7. History of alcohol dependence or drug abuse in the last 5 years or daily consumption of alcohol \> 40 g or high consumption of stimulating beverages (\> 5 coffees, teas or coca cola drinks/ day).
8. Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
9. Need of any prescription medication within 14 days prior to the administration of the drug and non prescription medication or herbal medicines within 7 days prior to the administration of the drug.
10. Participation in other clinical trials during the previous 90 days in which an investigational drug or a commercially available drug was tested.
11. Having donated blood during 4 weeks period before inclusion in the study.
12. Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.
13. 12 lead ECG obtained at screening with PR ≥ 220 msec, QRS ≥120 msec and QTc ≥ 440 msec, bradycardia (\<50 bpm) or clinically significant minor ST wave changes or any other abnormal changes on the screening ECG that would interfere with measurement of the QT interval.
14. Symptoms of a significant somatic or mental illness in the four week period preceding drug administration.
15. History of hepatitis HBV and / or HCV and / or positive serology results which indicate the presence of hepatitis B surface antigen and / or detectable HCV ribonucleic acid (RNA).
16. Positive results from the HIV serology.
17. Clinically significant abnormal laboratory values (as determined by the Principal Investigator) at the screening evaluation.
18. Positive results of the drugs at screening period or the day before starting treatment period. A minimum list of 6 drugs will be screened for inclusion: Amphetamines, Cocaine, Ethanol, Opiates, Cannabinoids and Benzodiazepines (positive results may be repeated at the discretion of the Principal Investigator).
19. Known hypersensitivity to the study drug or the composition of the galenical form.
20. History of psychiatric diseases or epileptic seizures.

Primary outcomes:
measure: Number of Participants with Serious and Non-Serious Adverse Events
timeFrame: day 0 to day 7
Secondary outcomes:
measure: Pharmacokinetic Profile Analysis (Plasma concentrations)
timeFrame: day 1
Other outcomes:
measure: Leeds Sleep Evaluation Questionnaire (LSEQ)
timeFrame: baseline and +24h
Locations:
city: Mataró
country: Spain
facility: Palobiofarma S.L. (molecule owner)
state: Barcelona
city: Barcelona
country: Spain
facility: CIM-Sant Pau - IIB Sant Pau, HSCSP
Study officials:
affiliation: CIM Sant Pau - IIB Sant Pau
name: Joan Martínez Colomer, MD
role: PRINCIPAL_INVESTIGATOR
References: